Optimization of metabolism to improve efficacy during CAR-T cell manufacturing
- PMID: 34876185
- PMCID: PMC8650271
- DOI: 10.1186/s12967-021-03165-x
Optimization of metabolism to improve efficacy during CAR-T cell manufacturing
Abstract
Chimeric antigen receptor T cell (CAR-T cell) therapy is a relatively new, effective, and rapidly evolving therapeutic for adoptive immunotherapies. Although it has achieved remarkable effect in hematological malignancies, there are some problems that remain to be resolved. For example, there are high recurrence rates and poor efficacy in solid tumors. In this review, we first briefly describe the metabolic re-editing of T cells and the changes in metabolism during the preparation of CAR-T cells. Furthermore, we summarize the latest developments and newest strategies to improve the metabolic adaptability and antitumor activity of CAR-T cells in vitro and in vivo.
Keywords: CAR-T; Glycolysis; Immunotherapy; Metabolism; OXPHOS.
© 2021. The Author(s).
Conflict of interest statement
The authors declare that there are no competing interests.
Figures
References
-
- Feng K, Guo Y, Dai H, et al. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer. Sci China Life Sci. 2016;59(5):468–479. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
